A Phase 2 interventional study of Placebo and Dupilumab SAR231893/REGN668 in Asthma, sponsored by Sanofi. Completed at 16 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 24th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 6th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2016.
This study's enrollment of 42 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 30th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2016, is one of 11 in phase 2, and was the 15th registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma.
Secondary Objective:
To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.
The total study duration for each participant was between approximately 29 and maximum of 30 weeks, consisting of a screening period of 5 weeks and optional up to 7 additional days, a treatment period of 12 weeks, and a post-treatment period of 12 weeks.
Participants who completed the treatment period could be eligible to participate in an open-label extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: Placebo · Drug: fluticasone propionate and salmeterol · Drug: budesonide and formoterol · Drug: mometasone furoate and formoterol
Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Drug: Dupilumab SAR231893/REGN668 · Drug: fluticasone propionate and salmeterol · Drug: budesonide and formoterol · Drug: mometasone furoate and formoterol
Pharmaceutical form:solution Route of administration: subcutaneous
Drug page: Dupilumab
Pharmaceutical form:solution Route of administration: subcutaneous
Drug pages: Fluticasone · Salmeterol Xinafoate
Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
Also known as: Advair
Drug pages: Budesonide · Formoterol
Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Also known as: Symbicort
Drug pages: Mometasone Furoate · Formoterol
Pharmaceutical form:inhalation aerosol Route of administration: inhaled
Also known as: Dulera
Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12
Inflammatory cells i.e. eosinophils were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
Time frame: Baseline, Week 12
Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12
Mucin was identified by staining with Alcian-blue periodic acid-Schiff and/or immunostaining for MUC5AC and then the mucin-positive area was measured and expressed per square millimeter.
Time frame: Baseline, Week 12
Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12
Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
Time frame: Baseline, Week 12
Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12
Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
Time frame: Baseline, Week 12
Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12
T-Lymphocytes i.e. CD3 positive cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
Time frame: Baseline, Week 12
Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12
T-helper i.e. CD4 positive lymphocytes were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
Time frame: Baseline, Week 12
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb.
Time frame: Baseline, Week 12
Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s, and reported in ppb. The average change in FeNO from baseline to Week 6 through Week 12 was calculated as follows: For each participant the change in FeNO from Baseline to Week 6, Week 8, Week 10 and Week 12 was calculated (value at Week X - value at baseline). Subsequently the weekly mean of these 4 "change from baseline" values was determined (Weeks 6, 8, 10 and 12). Using these weekly mean values the overall arithmetic mean and standard deviation of the average change in FeNO from baseline to Week 6 through Week 12 was calculated.
Time frame: From Baseline to Week 6 through Week 12
Number of Participants With Antidrug Antibodies (ADA)
Anti-drug antibodies were detected using a validated immunoassay. Incidence of ADA were classified as following: 1) Pre-existing immunoreactivity - an ADA positive response in the assay at baseline with all post treatment ADA results negative or an ADA positive response at baseline with all post treatment ADA responses less than 4-fold over baseline titer levels. 2) Treatment-emergent ADA: an ADA positive response in the assay post first dose, when baseline results were negative or missing. 3) Treatment-boosted ADA: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive.
Time frame: From Baseline up to 24 weeks
Pharmacokinetics (PK) Assessment: Serum Functional Dupilumab Concentration
Serum functional dupilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method.
Time frame: Week 0, Week 2, 6, 8, 12, 18, End of study (Week 24)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during between the first administration of study medication to the end of the 12 week Post-treatment Period. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.
Time frame: Baseline up to Week 24
The study was conducted at 16 sites in 6 countries. A total of 133 participants were screened between January 2016 and January 2018. Of which, 42 participants were randomized. 91 participants were screen failures mainly due to exclusion criteria met and inclusion criteria not met.
| Milestone | Placebo | Dupilumab |
|---|---|---|
| Started | 22 | 20 |
| Completed | 22 | 20 |
| Not completed | 0 | 0 |
Inflammatory cells i.e. eosinophils were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
| cells/mm^2 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12 | 5.80 (-9.18 to 33.41) | -6.04 (-174.71 to 19.41) |
Mucin was identified by staining with Alcian-blue periodic acid-Schiff and/or immunostaining for MUC5AC and then the mucin-positive area was measured and expressed per square millimeter.
| cells/mm^2 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12 | 64.09 ± 391.96 | -142.74 ± 477.89 |
Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
| cells/mm^2 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12 | -14.80 ± 76.52 | 1.76 ± 62.41 |
Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
| cells/mm^2 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12 | 2.37 ± 90.20 | -20.89 ± 59.09 |
T-Lymphocytes i.e. CD3 positive cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
| cells/mm^2 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12 | -36.70 (-200.25 to 267.51) | 34.21 (-95.08 to 232.99) |
T-helper i.e. CD4 positive lymphocytes were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
| cells/mm^2 | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12 | 7.26 (-179.43 to 224.96) | 62.34 (-100.62 to 159.09) |
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb.
| ppb | Placebo | Dupilumab |
|---|---|---|
| Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12 | 3.9 ± 22.8 | -15.1 ± 18.3 |
FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s, and reported in ppb. The average change in FeNO from baseline to Week 6 through Week 12 was calculated as follows: For each participant the change in FeNO from Baseline to Week 6, Week 8, Week 10 and Week 12 was calculated (value at Week X - value at baseline). Subsequently the weekly mean of these 4 "change from baseline" values was determined (Weeks 6, 8, 10 and 12). Using these weekly mean values the overall arithmetic mean and standard deviation of the average change in FeNO from baseline to Week 6 through Week 12 was calculated.
| ppb | Placebo | Dupilumab |
|---|---|---|
| Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12 | 3.5 ± 18.0 | -16.0 ± 21.0 |
Anti-drug antibodies were detected using a validated immunoassay. Incidence of ADA were classified as following: 1) Pre-existing immunoreactivity - an ADA positive response in the assay at baseline with all post treatment ADA results negative or an ADA positive response at baseline with all post treatment ADA responses less than 4-fold over baseline titer levels. 2) Treatment-emergent ADA: an ADA positive response in the assay post first dose, when baseline results were negative or missing. 3) Treatment-boosted ADA: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive.
| Participants | Placebo | Dupilumab |
|---|---|---|
| With pre-existing immunoreactivity | 1 | 0 |
| With treatment-emergent ADA | 0 | 1 |
| With treatment-boosted ADA | 0 | 0 |
Serum functional dupilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method.
| ng/mL | Dupilumab |
|---|---|
| Week 0 | 0.00 ± 0.00 |
| Week 2 | 52675.00 ± 23107.55 |
| Week 6 | 59969.00 ± 27422.27 |
| Week 8 | 61097.95 ± 29775.23 |
| Week 12 | 67387.00 ± 32800.44 |
| Week 18 | 20728.17 ± 17718.93 |
| Week 24 | 1851.20 ± 2796.78 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during between the first administration of study medication to the end of the 12 week Post-treatment Period. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.
| Participants | Placebo | Dupilumab |
|---|---|---|
| Any TEAE | 17 | 15 |
| Any treatment emergent SAE | 0 | 1 |
| Any TEAE leading to death | 0 | 0 |
| Any TEAE leading to permanent discontinuation | 0 | 0 |
Collected over All AEs were collected from signature of the informed consent form up to the end of study (i.e. up to the end of Post-treatment period [Week 24]) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/22 (0%) | 0/22 (0%) | 11/22 (50%) |
| Dupilumab | 0/20 (0%) | 1/20 (5%) | 14/20 (70%) |
| Event | Placebo | Dupilumab |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/22 | 1/20 |
| Event | Placebo | Dupilumab |
|---|---|---|
| HeadacheNervous system disorders | 3/22 | 5/20 |
| NasopharyngitisInfections and infestations | 4/22 | 2/20 |
| NauseaGastrointestinal disorders | 1/22 | 3/20 |
| Injection Site ErythemaGeneral disorders | 2/22 | 3/20 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/22 | 3/20 |
| Back PainMusculoskeletal and connective tissue disorders | 0/22 | 3/20 |
| VomitingGastrointestinal disorders | 0/22 | 2/20 |
| Injection Site PruritusGeneral disorders | 1/22 | 2/20 |
| Accidental OverdoseInjury, poisoning and procedural complications | 1/22 | 2/20 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 0/22 | 2/20 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Mean | 41.0 ± 10.3 | 45.5 ± 10.6 | 43.1 ± 10.6 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Female | 8 | 13 | 21 |
| Male | 14 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 21 | 19 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Dupilumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 6 |
| White | 19 | 16 | 35 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Eosinophils Count in Bronchial Tissue(cells/mm^2) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Median | 12.97 (9.91 to 21.24) | 34.96 (10.07 to 263.75) | 20.73 (9.99 to 68.87) |
| Baseline Mucin-Stained Area in The Bronchial Tissue Specimen(cells/mm^2) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Mean | 561.12 ± 289.00 | 520.57 ± 511.69 | 542.33 ± 402.61 |
| Baseline Mast Cells Count (Chymase Positive) in Bronchial Tissue(cells/mm^2) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Mean | 74.36 ± 58.63 | 79.17 ± 68.07 | 76.59 ± 62.42 |
| Baseline Mast Cells Count (Tryptase Positive) in Bronchial Tissue(cells/mm^2) | Placebo | Dupilumab | Total |
|---|---|---|---|
| Mean | 80.10 ± 64.92 | 105.53 ± 104.68 | 91.88 ± 85.49 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jan 2016 to primary completion in Jan 2018, 23 months.
Results were first posted in Jan 2019, 1 year after primary completion.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab